Results 161 to 170 of about 16,167 (200)

3,3-Bisaryloxindoles as mineralocorticoid receptor antagonists

Bioorganic & Medicinal Chemistry Letters, 2005
Syntheses and SAR studies of 3,3-bisaryloxindole analogues provided potent mineralocorticoid receptor (MR) antagonists that were selective over other steroid nuclear hormone receptors.
David A, Neel, Matthew L, Brown, Peter A, Lander, Timothy A, Grese, Jean M, Defauw, Robert A, Doti, Todd, Fields, Sally Ann, Kelley, Stephon, Smith, Karen M, Zimmerman, Mitchell I, Steinberg, Prabhakar K, Jadhav   +11 more
openaire   +3 more sources

Mineralocorticoid Receptor Antagonists in Primary Aldosteronism

Current Pharmaceutical Design, 2019
Background:Primary aldosteronism is the most common causes of secondary hypertension. Patients suffering from this clinical syndrome have an increased cardiovascular risk and target organ damage. Mineralocorticoid receptor antagonists are the optimal pharmaceutical option for the management of such patients.Objectives:The study aimed to assess the ...
Konstantinos, Stavropoulos, Christodoulos, Papadopoulos, Konstantinos, Koutsampasopoulos, Georgios, Lales, Christos, Mitas, Michael, Doumas   +5 more
openaire   +2 more sources

Nonsteroidal antagonists of the mineralocorticoid receptor

Current Opinion in Nephrology and Hypertension, 2015
The broad clinical use of steroidal mineralocorticoid receptor antagonists (MRAs) is limited by the potential risk of inducing hyperkalemia when given on top of renin-angiotensin system blockade. Drug discovery campaigns have been launched aiming for the identification of nonsteroidal MRAs with an improved safety profile.
Peter, Kolkhof, Christina, Nowack, Frank, Eitner   +2 more
openaire   +2 more sources

Non-steroidal mineralocorticoid receptor antagonists

Expert Opinion on Therapeutic Patents, 2007
The mineralocorticoid hormone aldosterone is essential in regulating the body’s salt and water balance. However, abnormal activation of the mineralocorticoid receptor (MR) by elevated levels of aldosterone and salt imbalance cause hypertension and other effects detrimental to the cardiovascular system. Thus, MR antagonists are expected to be beneficial
Marvin J Meyers, Xiao Hu
openaire   +1 more source

Aldosterone, Mineralocorticoid Receptor and the Metabolic Syndrome:Role of the Mineralocorticoid Receptor Antagonists

Current Vascular Pharmacology, 2012
Several lines of evidence suggest a detrimental effect of aldosterone excess on the development of metabolic alterations. Glucose metabolism derangements due to aldosterone action are frequently observed not only in patients with primary aldosteronism but also in patients with obesity. A contribution to the hyperaldosteronism observed in obese subjects
Ronconi, Vanessa, Turchi, Federica, Appolloni, Gloria, di Tizio, Valentina, BOSCARO, MARCO, Giacchetti, Gilberta   +5 more
openaire   +3 more sources

Emerging cardiovascular indications of mineralocorticoid receptor antagonists

Trends in Endocrinology & Metabolism, 2015
Mineralocorticoid receptor (MR) antagonism is a well-established treatment modality for patients with hypertension, heart failure, and left ventricular systolic dysfunction (LVSD) post-myocardial infarction (MI). There are emerging data showing potential benefits of MR antagonists in other cardiovascular conditions.
Parviz, Yasir, Iqbal, Javaid, Pitt, Bertram, Adlam, David, Al-Mohammad, Abdallah, Zannad, Faiez   +5 more
openaire   +2 more sources

Adverse Effects of Mineralocorticoid Receptor Antagonist Administration

Current Pharmaceutical Design, 2019
Background: Mineralocorticoid receptor antagonists consist of a class of drugs with pleiotropic beneficial effects in several cardiovascular diseases. However, physicians frequently overlook their use due to the adverse effects of such agents. Objectives: To determine the adverse effects of mineralocorticoid receptor antagonists and to suggest ...
Manolis S, Kallistratos, Andreas, Pittaras, Iakovos, Theodoulidis, Charris, Grassos, Leonidas E, Poulimenos, Athanasios J, Manolis   +5 more
openaire   +2 more sources

Mineralocorticoid receptor antagonists (MRAs)

2014
Abstract The final process in the renin–angiotensin–aldosterone system (RAAS) is the production of the mineralocorticoid aldosterone in the adrenal glands. Aldosterone has an important role in the pathophysiology of heart failure, and concentrations of aldosterone are 20-fold higher in patients with HF compared to normal individuals ...
Roy S. Gardner, Theresa A. McDonagh, Niki L. Walker   +2 more
openaire   +1 more source

Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist

Nature Clinical Practice Endocrinology & Metabolism, 2008
Increasing recognition of the role of aldosterone in cardiovascular disease has been supported by a significant body of evidence from animal models. This evidence has been translated into clinical practice, and large-scale, randomized, placebo-controlled trials have confirmed the beneficial effects of mineralocorticoid blockade in patients with heart ...
McManus, Frances, McInnes, Gordon T, Connell, John M C   +2 more
openaire   +3 more sources

Mineralocorticoid receptor antagonists in kidney transplantation

European Journal of Clinical Investigation
AbstractBackgroundThe fundamental role of the renin–angiotensin–aldosterone system in the pathophysiology of chronic kidney disease, congestive heart failure, hypertension and proteinuria is well established in pre‐clinical and clinical studies. Mineralocorticoid receptor antagonists are among the primary options for renin–angiotensin–aldosterone ...
Mehmet Kanbay, Sidar Copur, Berk Mizrak, Francesca Mallamaci, Carmine Zoccali   +4 more
openaire   +2 more sources